National Comprehensive Cancer Network, 2020, NCCN Clinical Practice Guidelines in Oncology. Version 1.2021. Chronic Lymphocytic leukemia/Small Lymphocytic Lymphoma
Shi, 2013, The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies, J Hematol Oncol., 6, 74, 10.1186/1756-8722-6-74
Bose, 2013, Cyclin-dependent kinase inhibitor therapy for hematologic malignancies, Expert Opin Investig Drugs., 22, 723, 10.1517/13543784.2013.789859
Li, 2015, Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1, Leukemia., 29, 1702, 10.1038/leu.2015.99
Gregory, 2015, CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo, Leukemia., 29, 1437, 10.1038/leu.2015.10
Hossain, 2018, Dinaciclib induces immunogenic cell death and enhances anti-PD1-mediated tumor suppression, J Clin Invest., 128, 644, 10.1172/JCI94586
Chen, 2019, Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087, Blood., 134, 1144, 10.1182/blood.2019000324
Armand, 2019, Pembrolizumab in relapsed or refractory primary mediastinal large b-cell lymphoma, J Clin Oncol., 37, 3291, 10.1200/JCO.19.01389
Flynn, 2015, Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia, Leukemia., 29, 1524, 10.1038/leu.2015.31
Gojo, 2013, Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias, Cancer Chemother Pharmacol., 72, 897, 10.1007/s00280-013-2249-z
Kumar, 2015, Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma, Blood., 125, 443, 10.1182/blood-2014-05-573741
Baiocchi, 2010, Early evidence of anti-lymphoma activity of the cyclin dependent kinase inhibitor dinaciclib (sch 727965) in heavily pre-treated low grade lymphoma and diffuse large cell lymphoma patients, Blood., 116, 3966, 10.1182/blood.V116.21.3966.3966
Badros, 2017, Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma, Blood., 130, 1189, 10.1182/blood-2017-03-775122
Ji, 2013, Modified toxicity probability interval design: a safer and more reliable method than the 3 + 3 design for practical phase I trials, J Clin Oncol., 31, 1785, 10.1200/JCO.2012.45.7903
Hallek, 2008, Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines, Blood., 111, 5446, 10.1182/blood-2007-06-093906
Cheson, 2007, Revised response criteria for malignant lymphoma, J Clin Oncol., 25, 579, 10.1200/JCO.2006.09.2403
Durie, 2006, International uniform response criteria for multiple myeloma [published corrections appear in Leukemia. 2006;20(12):2220 and 2007;21(5):1134], Leukemia., 20, 1467, 10.1038/sj.leu.2404284
Ribrag, 2019, Phase 1b trial of pembrolizumab monotherapy for relapsed/refractory multiple myeloma: KEYNOTE-013, Br J Haematol., 186, e41, 10.1111/bjh.15888
Usmani, 2019, Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial, Lancet Haematol., 6, e448, 10.1016/S2352-3026(19)30109-7
Mateos, 2019, Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial, Lancet Haematol., 6, e459, 10.1016/S2352-3026(19)30110-3
Armand, 2021, A phase 1b study of dual PD-1 and CTLA-4 or KIR blockade in patients with relapsed/refractory lymphoid malignancies, Leukemia., 35, 777, 10.1038/s41375-020-0939-1
Zinzani, 2019, Nivolumab combined with brentuximab vedotin for relapsed/refractory primary mediastinal large B-cell lymphoma: efficacy and safety from the phase ii checkmate 436 study, J Clin Oncol., 37, 3081, 10.1200/JCO.19.01492
Godfrey, 2019, PD-L1 gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype, Blood., 133, 2279, 10.1182/blood-2018-10-879015
Wright, 2020, A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications, Cancer Cell., 37, 551, 10.1016/j.ccell.2020.03.015